Compare Crowdstrike Holdings Inc (CRWD) vs Twist Bioscience Corp (TWST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crowdstrike Holdings Inc vs Twist Bioscience Corp — how do they compare? Crowdstrike Holdings Inc trades at $221.58 (market cap $225.95B), while Twist Bioscience Corp trades at $124.75 (market cap $7.72B). The key difference: Crowdstrike Holdings Inc is far larger — about 29.3× Twist Bioscience Corp's market cap. Which is the better fit depends on your goals.
| CRWD | TWST | |
|---|---|---|
Market Cap | $225.95B | $7.72B |
Sector | Technology | Health |
52-Week High | $225.16 | $124.88 |
52-Week Low | $87.56 | $24.16 |
Enterprise Value | $222.22B | $7.65B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CrowdStrike (CRWD) trades at $221.01, down 1.84% today, but maintains a strong technical uptrend with bullish moving averages and support at $219. The stock has delivered consistent earnings beats, with Q1 2026 EPS of $0.28 exceeding the $0.27 estimate. Revenue growth remains robust, climbing to $3.95 billion in 2025, though net margins are slightly negative. Recent positive news includes being named a leader in IDC's MDR/MXDR report (Business Wire, August 11, 2026) and surging cybersecurity sector interest.
Outlook is cautiously optimistic given strong revenue expansion and platform adoption, but high valuation multiples (P/E 765.02, P/S 44.07) pose risks. Analyst consensus is bullish with 76% buy ratings and a $191.74 price target, though current price exceeds this. Key risks include premium valuation sensitivity, competitive pressures, and macroeconomic impacts on tech spending.
Twist Bioscience (TWST) trades at $123.76, down 0.9% on the day, with a bullish technical signal from moving averages but bearish oscillators. Revenue growth is strong, with 2025 revenue at $376.57 million, though the company remains unprofitable with a net income margin of -31.66%. Recent news highlights an upsized $300 million public offering and an analyst upgrade, contributing to positive sentiment.
The outlook is mixed: robust revenue growth and high analyst buy ratings (78.57%) support upside potential, but persistent losses, negative cash flow, and high valuation ratios pose significant risks. Investors should weigh the growth trajectory against the path to profitability and cash burn concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Crowdstrike Holdings Inc
CrowdStrike Holdings provides cybersecurity products and services aimed at protecting organizations from cyberthreats. It offers cloud-delivered protection across endpoints, cloud workloads, identity and data, and threat intelligence, managed security services, IT operations management, threat hunting, identity protection, and log management. CrowdStrike went public in 2019 and serves customers worldwide.
Read more on CRWD →About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →
